This is a special episode brought to you in association with Hepatology Knowledge into Practice.

People with type 2 diabetes or obesity are at higher risk of developing non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH). Some estimates report a prevalence of NAFLD of 60% in people with type 2 diabetes, rising to 78% in those who also have obesity. So what’s behind this link?

In this podcast episode, Professor Giulio Marchesini explores the relationships between NAFLD, type 2 diabetes and obesity and offers advice for healthcare professionals caring for people with one or more of these conditions.

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References available here

Disclosures: Prof. Giulio Marchesini declares the following:

Advisory Board: Novartis, Eli Lilly, Gilead, MSD, Pfzier, Astra-Zeneca

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.